ADAM Metalloproteinases as Potential Drug Targets

Curr Med Chem. 2019;26(15):2661-2689. doi: 10.2174/0929867325666180326164104.

Abstract

The ADAMs, together with ADAMTSs and snake venom metalloproteases (SVMPs), are members of the Adamalysin family. Differences in structural organization, functions and localization are known and their domains, catalytic or non-catalytic, show key roles in the substrate recognition and protease activity. Some ADAMs, as membrane-bound enzymes, show sheddase activity. Sheddases are key to modulation of functional proteins such as the tumor necrosis factor, growth factors, cytokines and their receptors, adhesion proteins, signaling molecules and stress molecules involved in immunity. These activities take part in the regulation of several physiological and pathological processes including inflammation, tumor growth, metastatic progression and infectious diseases. On these bases, some ADAMs are currently investigated as drug targets to develop new alternative therapies in many fields of medicine. This review will be focused on these aspects.

Keywords: Metalloendopeptidases; adhesion molecules; ectodomain shedding; hydroxamate inhibitors; small molecules; zincbinding group..

Publication types

  • Review

MeSH terms

  • ADAM Proteins / antagonists & inhibitors*
  • ADAM Proteins / chemistry
  • ADAM Proteins / metabolism
  • ADAM Proteins / physiology
  • Animals
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Catalytic Domain
  • Cell Line, Tumor
  • Humans
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Protease Inhibitors
  • ADAM Proteins